Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

NCT06796504 is registered in ClinicalTrials.gov with SetPoint Medical Corporation as lead sponsor.

NCT NCT06796504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06796504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
Lead sponsor
SetPoint Medical Corporation
Phase
Not applicable
Overall status
Recruiting
Start date
April 17, 2026
Completion date
September 30, 2030
Enrollment
60 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis